Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 977
countries
28
conditions
2 105

11 trials match your criteria

Hormone-refractory prostate cancer

Recruiting

A Study of Tulmimetostat and Luxdegalutamide Compared to Standard Treatment in Men with Advanced Prostate Cancer That No Longer Responds to Hormone Therapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Hormone-refractory prostate cancer

Recruiting

Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel

Hormone-refractory prostate cancer

Recruiting

Study of Ebastine and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients with Advanced Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel

Hormone-refractory prostate cancer+2

Recruiting

Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Prostate cancer

Recruiting

Study on the Effect of Metastasis-Directed Therapy with Lutetium (177Lu) Zadavotide Guraxetan in Patients with Advanced Prostate Cancer and Up to 5 Progressive Lesions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Hormone-refractory prostate cancer

Recruiting

Study on Docetaxel, Cabazitaxel, and Darolutamide for Men with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Prostate cancer

Not recruiting

A Study of Cabazitaxel and Pelvic Radiation Therapy Combined with Hormone Treatment for Patients with High-Risk Localized Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel

Prostate cancer metastatic+1

Not recruiting

Study of Pembrolizumab, Carboplatin, and Cabazitaxel for Patients with Aggressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel

Hormone-refractory prostate cancer+1

Not recruiting

Study of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.